Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

BioMarin drug becomes first U.S. approved therapy for dwarfism

Published 11/19/2021, 03:01 PM
Updated 11/19/2021, 03:06 PM
© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

(Reuters) - BioMarin Pharmaceutical (NASDAQ:BMRN) Inc's once-daily injection for children with the most common type of dwarfism received clearance from the U.S. health regulator on Friday, making it the first approved therapy for achondroplasia in the country.

The approval for Voxzogo, intended for children aged five and older, comes months after it became the first therapy to be greenlighted by regulators for the treatment of the genetic condition in Europe.

Many countries still do not have an approved therapy for Achondroplasia, a condition characterized by short stature which occurs in about one in every 25,000 newborns worldwide.

BioMarin expects the therapy's annual net revenue per patient in the United States to be about $240,000 and expects about 3,000 children with achondroplasia in the country to be eligible for the treatment. Voxzogo is expected to be available in the United States by mid-to-late December at a list price of $899 per vial, the company said.

BioMarin's late-stage Voxzogo study showed improvements in patients' growth rate over a year and was well tolerated. The drug is also being studied in children below five years and has already been approved in Europe for those aged two and above.

The U.S. Food and Drug Administration had in April extended the review of the drug by three months to assess two-year data on the drug.

It has now cleared the drug under the accelerated approval pathway, which requires a post-marketing study assessing final adult height.

© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

BioMarin said it intended to use the results from ongoing extension studies to receive final approval.

The drug is also under regulatory review in Japan, Brazil, and Australia and could receive approval in the countries next year, BioMarin said.

Latest comments

In short that was a tall monumental achievement
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.